Panacea Biotec launches diabetes drug in India
Panacea Biotec is pleased to announce launch of brand ViLACT in India. ViLACT is used in the treatment of Uncontrolled Type 2 Diabetes Mellitus patients with HbA1c >6.5%. VilACT is available in four formulations: 1. ViLACT : Vildagliptin 50 mg Tablet. 2. ViLACT M 500 : Vildagliptin 50 mg + Metformin HCL 500 mg Tablet. 3. ViLACT M 850 : Vildagliptin 50 mg + Metformin HCL 850 mg Tablet. 4. ViLACT M 1000 : Vildagliptin 50 mg + Metformin HCL 1000 mg Tablet. The total market size of this molecule and its combination is Rs 969 Crore as per AIOCD MAT October
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
